1 advisor for enterprise management theNo

In 2009, IPTV'sindustrial applications will expand their scope. IPTV industrial applicationsshould be considered as breakthroughs, accelerating regional layout so as todrive the local public user market's growth.About CCID ConsultingCCID Consulting Co., Ltd. (hereinafter known as CCID Consulting), thefirst Chinese consulting firm listed in the Growth Enterprise Market of theStock Exchange (GEM) of Hong Kong (stock code: 8235.HK), is directlyaffiliated with China Center for Information Industry Development (hereinafterknown as CCID Group). Thecompany's business scope has covered over 200 large and medium-sized cities inChina.Based on major areas of competitiveness: industrial resources, informationtechnology and data channels, CCID Consulting provides customers with publicpolicy establishment, industry competitiveness upgrading, development strategyand planning, marketing strategy and research, HR management, IT programmingand management. CCID Consulting's customers range from industrial users inelectronics, telecommunications, energy, finance, automobile, to governmentdepartments at all levels and diversified industrial parks CCID Consultingcommits itself to becoming the No. 1 advisor for enterprise management, theNo.1 consultancy for government decisions and the No. at86-10-8855-9080 or .

GUANGZHOU, China, Jan. 5 /PRNewswire-Asia/ China Medicine Corporation(OTC Bulletin Board: CHME) ("China Medicine" or "the Company"), a leadingdeveloper and distributor of prescription and over the counterpharmaceuticals,traditional Chinese medicines (TCM), nutritional and dietary supplements,medical devices and medical formulations, announced today that it has renewedits contract with CCG Investor Relations for a primary term of one yearcommencing on January 1, 2009."After one year of service, we are happy to renew our contract and haveCCG Investor Relations continue to design and execute our investor relationscampaign," said Mr. Senshan Yang, Chief Executive Officer of China Medicine."We are looking forward to utilizing CCG's full set of services to furtherraise our visibility in the investment community and support the rollout ofrecombinant Aflatoxin Detoxifizyme (rADTZ), our innovative product that hasthe potential to detoxify aflatoxin (AFT), a potential cancer causing agent,in food and feed."China Medicine operates through its 100-owned subsidiary, GuangzhouKonzern Pharmaceutical Company Ltd ("Konzern"). After the success of a reverse merger of Konzerninto a public shell company in 2006, the Company ventured into research anddevelopment by establishing Guangzhou Co-win Bioengineering Co., Ltd.

Dongsheng Yao,in which the Company, through Konzern, owns 70 equity interest. The rADTZproject has received a government grant and will continue to receive financialsupport from the government as one of "863" key projects startingcommercialization after more than ten years of research and incubation."The harmful threat of aflatoxins presents an opportunity for ChinaMedicine to increase the quality and standard of animal feed and human food,"commented Crocker Coulson, President of CCG Investor Relations. "We intend todevelop a well-orchestrated investor relations program to enhance ChinaMedicine's profile in the investment community and will also assist theCompany in educating investors about its new product strategy and line ofinnovative products."About China Medicine CorporationChina Medicine Corporation is a leading pharmaceutical company whichdiscovers, develops, and distributes over 2,300 pharmaceutical products inChina including prescription and over the counter ("OTC") drugs, traditionalChinese medicine ("TCM") products, herbs and dietary supplements. The Companydistributes the products to wholesale distributors in 28 provinces, over 300hospitals, 500 medicine companies, and 1,788 drug stores throughout China.

TheCompany actively develops a number of proprietary products for many usesincluding oncology, high blood pressure and the removal of toxins from foodand animal feeds. For more information visit the Company's website at http:// .Those who are interested in ADTZ could goto the website and read the white paper under R&D section.Cautionary StatementThis press release contains forward-looking statements concerning theCompany's business and products. The Company's actual results may differmaterially depending on a number of risk factors including, but not limitedto,the following: general economic and business conditions, obtaining regulatoryapproval for new products, the expected contribution of higher marginproducts,government support for rural health care, competition from existing and newcompetitors, changes in technology, and various other factors beyond itscontrol. ChinaMedicine Corporation undertakes no duty to revise or update anyforward-looking statements to reflect events or circumstances after the dateof this release.For more information, please contact:Company Contact: Ms. Crocker Coulson President CCG Investor Relations Tel: 1-646-213-1915 (NY Office) Email: SOURCEChina Medicine CorporationMs.